Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …

Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …

Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …

PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor
(EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …

Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …

Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to
treat patients with EGFR T790M-positive non–small cell lung cancer (NSCLC) who have …

Importance Although treatment with first-generation epidermal growth factor receptor (EGFR)–
tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies …

Inspired by the success of dual-targeting drugs, especially bispecific antibodies, we propose
to combine the concept of proteolysis targeting chimera (PROTAC) and dual targeting to …

PURPOSE To investigate the efficacy of gefitinib as an adjuvant therapy for non–small-cell
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …